Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis

M. Meissner, Y. Sherer, Y. Levy, H. Chwalinska-Sadowska, P. Langevitz, Y. Shoenfeld*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


The use of intravenous immunoglobulin (IVIg) has been reported as an immunomodulating agent in several autoimmune diseases, including systemic lupus erythematosus (SLE). Herein we report a SLE patient with severe clinical presentation that included pericarditis, pleural effusion, nephrotic range proteinuria, leukopenia, and lymphopenia. The patient received one course of high-dose IVIg (2.8 g/kg body weight), and within a week of post-IVIg therapy, her condition significantly improved. One-month post-IVIg there were decreased proteinuria, elevated leukocytes and lymphocytes count, decrease in antinuclear and anti-dsDNA antibodies, and disappearance of pericarditis and pleuritis. This case demonstrates the efficacy of IVIg in severe SLE with various clinical manifestations.

Original languageEnglish
Pages (from-to)199-201
Number of pages3
JournalRheumatology International
Issue number5
StatePublished - 2000
Externally publishedYes


  • Intravenous immunoglobulin
  • Pericarditis
  • Pleural effusion
  • Proteinuria
  • Systemic lupus erythematosus


Dive into the research topics of 'Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis'. Together they form a unique fingerprint.

Cite this